The Landscape of Asthma Research in the United States
More than 25 million Americans live with asthma, yet many still struggle to keep symptoms in check. A focus group study conducted across three US cities found that only 28% of adult asthma patients had well-controlled symptoms according to standard assessment tools, and 44% admitted they were not following their prescribed treatment plan. This gap between what current medications offer and what patients experience day to day is exactly what drives the steady stream of clinical trials happening right now.
The research landscape has shifted in notable ways over the past few years. Biologic therapies, which target specific inflammatory pathways rather than broadly suppressing the immune system, have become a major area of investigation. In April 2026, Breztri Aerosphere became the first triple-combination therapy approved for asthma in patients 12 and older, building on positive results from the KALOS and LOGOS Phase III trials. Meanwhile, several investigational drugs are making their way through clinical testing—brenipatide from Eli Lilly, GB-0895 from Generate Biomedicines, and solriktug from Uniquity One, to name a few. Each represents a slightly different angle on managing moderate to severe asthma that has not responded well to standard inhaled corticosteroids.
Trial locations tend to cluster around major academic medical centers. Boston, Houston, Denver, and the Research Triangle area in North Carolina are particularly active hubs. That said, many sponsors now work with regional clinics and community hospitals to expand access, so living far from a major city does not automatically disqualify you.
What Participation Actually Involves
The term "clinical trial" can sound intimidating, but the day-to-day experience is often more straightforward than people expect. Most asthma studies fall into one of three categories: trials testing an entirely new medication, trials comparing existing treatments in new combinations, and observational studies that track how patients manage their condition over time without changing their regimen.
Screening comes first. Before you commit to anything, the research team will review your medical history, run breathing tests like spirometry, and sometimes draw blood to check for specific biomarkers. At the University of Virginia's Asthma and Allergy division, for instance, the screening process can involve up to three visits and includes allergy skin testing and lung function assessments. If you qualify, you move into the treatment phase.
The treatment phase varies widely. Some studies last only a few weeks with a handful of visits. Others, particularly those testing biologic injections, can stretch over 50 or 60 weeks with regular check-ins. The SOLAIRIA-2 study investigating GB-0895 for severe uncontrolled asthma, for example, is designed as a randomized, double-blind trial where participants receive either the investigational drug or a placebo alongside their usual controller medications. During visits, you will typically complete questionnaires about your symptoms, undergo lung function tests, and meet with the study coordinator to review any changes.
Safety monitoring is built in. Every trial has what is called a data monitoring committee—an independent group that reviews incoming results and can halt the study if safety concerns arise. You can also withdraw at any time, for any reason, without penalty.
Here is a snapshot of the kinds of asthma trials currently recruiting in the US and how they compare:
| Trial Type | Example Study | Typical Duration | Ideal Candidate Profile | Key Consideration |
|---|
| Biologic (new target) | GB-0895 (SOLAIRIA-2) | 50–60 weeks | Severe asthma uncontrolled on ICS plus controllers | May require regular injections at clinic |
| Triple-combination inhaler | Breztri (KALOS/LOGOS) | 24–52 weeks | Moderate to severe asthma, age 12+ | Single-inhaler convenience; already approved |
| Rescue-combination inhaler | Fluticasone/Albuterol (Teva) | 12–26 weeks | Mild to moderate asthma with exacerbation history | Uses "as needed" dosing approach |
| Biologic (established) | Tezepelumab (TAPER) | 40–60 weeks | Severe asthma, currently on biologic therapy | Explores reducing background meds |
| Early-phase (Phase 1/2) | PRA-216 (Prana Therapies) | 12–24 weeks | Mild to moderate asthma | Smaller participant pool; more frequent monitoring |
Real Experiences and Practical Considerations
A patient named Sarah, who participated in an asthma biologic trial in the Midwest, shared that the biggest surprise was how much time the study team spent explaining each step. "I thought I would just show up, take a pill, and leave," she said. "But they walked me through every questionnaire, every breathing test. It felt less like being a guinea pig and more like having a second set of doctors focused entirely on my lungs."
That sentiment echoes what many former participants report. The trade-off, however, is the time commitment. Trials with longer duration often require visits every two to four weeks. If your schedule is already tight, a shorter observational study or a focus group—which typically pays between $100 and $350 for a single session—might be a better fit.
Compensation varies significantly. Shorter focus groups and survey panels tend to fall in the lower range, while full clinical trials offer more substantial payments to reflect the time and travel involved. For reference, the Brigham and Women's Hospital Asthma Research Center has offered participants up to $3,900 for completing 26 onsite visits over 22 months. Clinical Research of West Florida has paid up to $1,100 for asthma trial participation, and the University of Wisconsin has offered up to $1,350. Screening visits are often compensated separately, sometimes in the $50 to $125 range. These amounts are not guaranteed and depend on the specific study protocol, so always confirm the compensation structure during the informed consent discussion.
Travel costs are another factor. Some sponsors reimburse for mileage or arrange transportation, but this is not universal. If you live in a rural area, ask upfront whether the study covers travel expenses or offers remote check-in options for some visits.
A common concern among potential participants is whether they might receive a placebo instead of the active treatment. In many asthma trials, particularly those testing new drugs against existing standard-of-care treatments, every participant continues taking their usual controller medications. The investigational drug (or placebo) is added on top. This design means you are not left untreated regardless of which group you are assigned to. The study coordinator will explain the specific design during the consent process.
How to Find a Trial That Fits
Start with ClinicalTrials.gov, the federal registry maintained by the National Library of Medicine. You can filter by condition ("asthma"), location (city, state, or distance from your ZIP code), and recruitment status ("recruiting" or "not yet recruiting"). The site lists study purpose, eligibility criteria, locations, and contact information for each trial.
Beyond the federal database, patient advocacy organizations like the Asthma and Allergy Foundation of America maintain directories of active studies. Academic medical centers often have dedicated research recruitment pages—check the websites of major hospitals in your region. The American Lung Association also provides resources for connecting patients with research opportunities.
A few practical steps to take before reaching out:
- Gather your medical records, particularly your most recent pulmonary function test results and a list of current medications. Many trials require specific lung function thresholds, such as an FEV1 within a certain percentage of predicted normal.
- Write down your asthma history: age at diagnosis, frequency of exacerbations over the past year, any emergency room visits or hospitalizations, and which medications you have tried and why they did or did not work.
- Prepare questions for the screening call. Ask about the time commitment, the number of visits, whether compensation is provided, how travel is handled, and what happens when the trial ends.
- Be honest about your schedule. If you travel frequently for work or have caregiving responsibilities that make weekly visits impractical, mention it early.
The people running these studies genuinely want participants who can complete the protocol. Being upfront about constraints helps everyone.
If you have been frustrated by asthma that refuses to settle down despite your best efforts, exploring clinical research might open a door you had not considered. The process requires patience and a willingness to show up, but for many participants, the combination of expert medical attention, access to emerging therapies, and the knowledge that you are helping shape future treatment options makes the effort worthwhile.
研究の知恵